Abstract Number: 0209 • ACR Convergence 2023
Safety of Bivalent SARS-CoV-2 Vaccines as a Second Booster Dose in Arthritis Patients on Immunosuppressive Therapies
Background/Purpose: Safety and efficacy of updated bivalent vaccines, containing both the original vaccine variant of SARS-CoV-2 Spike and either Omicron variants BA.1 or BA.4/5, are…Abstract Number: 0225 • ACR Convergence 2023
Breakthrough SARS-Cov-2 Infection and Disease Flares in Patients with Rheumatoid Arthritis: Result from COVAD E-Survey Study
Background/Purpose: Existing studies have shown that disease activity of patients with rheumatoid arthritis (RA) may surge after COVID-19 infection. However, factors associated with disease flares…Abstract Number: 1158 • ACR Convergence 2023
Dermatomyositis Flares After COVID-19 Vaccination and/or SARS-CoV-2 Infection
Background/Purpose: Dermatomyositis (DM) is an autoimmune disorder part of the group of idiopathic inflammatory myopathies. It is characterized by proximal muscle weakness and skin involvement.…Abstract Number: 1772 • ACR Convergence 2023
Rheumatoid Arthritis-Specific Rheumatoid Factors Develop in Some COVID-19 Patients
Background/Purpose: Rheumatoid factors (RFs), antibodies canonically known to bind two conformational epitopes of IgG Fc, are a hallmark of rheumatoid arthritis (RA) but also can…Abstract Number: 2038 • ACR Convergence 2023
Impact of COVID-19 Pandemic on Preventative Health Screenings in Rheumatology Outpatients
Background/Purpose: The COVID-19 pandemic created significant barriers to accessing recommended preventative health screening. Patients already managing a chronic disease, particularly those using immunosuppressive medications, may…Abstract Number: 2567 • ACR Convergence 2023
An Extended Interval Between mRNA COVID-19 Booster Vaccinations Is Associated with an Increased Humoral Immune Response in Patients with Inflammatory Rheumatic Diseases
Background/Purpose: There is evidence that extending the interval between COVID-19 vaccination doses is associated with increased immunogenicity and neutralizing activity in healthy individuals (1, 2).…Abstract Number: 0210 • ACR Convergence 2023
Longitudinal T Cell Responses to a Series of Four SARS-CoV-2 Vaccine Doses or COVID-19 in Patients on TNF Inhibitors
Background/Purpose: T cells are critical for control of viral infection with SARS-CoV-2, but knowledge is lacking on cellular immune responses following repeated vaccination and breakthrough…Abstract Number: 0226 • ACR Convergence 2023
Relationships Among Parameters of Mineral Metabolism and Bone Turnover During Acute COVID-related Hospitalization and Subsequent Follow Up: A Pilot Study
Background/Purpose: Inflammatory conditions can exert direct adverse effects on bone metabolism, via increased bone resorption with inadequate compensatory bone formation. COVID-19 has been associated with…Abstract Number: 1166 • ACR Convergence 2023
Patients with COVID-19 and Polymyositis Inpatient Outcomes and Hospital Cost: Nationwide Inpatient Sample 2020
Background/Purpose: During the COVID-19 pandemic, there were growing concerns regarding the impact of SARS-CoV-2 on not only patients with rheumatic diseases but also the national…Abstract Number: 1796 • ACR Convergence 2023
Safety & ImmUnogenicity of COVID-19 VaCcines in SystEmic immunE Mediated Inflammatory Diseases (SUCCEED)
Background/Purpose: The Canadian government's COVID Immunity Task Force funded SUCCEED to study COVID vaccination responses in immune-mediated inflammatory disease(IMID). We describe how drugs, clinical factors,…Abstract Number: 2040 • ACR Convergence 2023
Distinguishing Multisystem Inflammatory Syndrome in Children from Typhus Using Artificial Intelligence: MISC vs. Endemic Typhus (AI-MET)
Background/Purpose: Multisystem inflammatory syndrome in children (MIS-C) following SARS-CoV2infection is a recognized mimic of other inflammatory disorders, including Kawasaki Disease and macrophage activation syndrome. However,…Abstract Number: 2568 • ACR Convergence 2023
First Breakthrough COVID-19 Infection Following Two SARS-CoV-2 Vaccinations Among Primary Systemic Vasculitis Patients
Background/Purpose: Primary systemic vasculitis (PSV) patients on immunosuppression are at higher risk of adverse outcomes following COVID-19 infection and often mount suboptimal vaccine responses to…Abstract Number: 070 • 2023 Pediatric Rheumatology Symposium
The Impact of the COVID-19 Pandemic on Patients with Juvenile Idiopathic Inflammatory Myopathies
Background/Purpose: Since the onset of the COVID-19 pandemic, there have been concerns regarding the risks of SARS-CoV-2 infection in patients with juvenile idiopathic inflammatory myopathies…Abstract Number: 076 • 2023 Pediatric Rheumatology Symposium
COVID-Distress in Children with Systemic Lupus Erythematosus During the COVID-19 Pandemic
Background/Purpose: Psychological symptoms are common in childhood-onset systemic lupus erythematosus (cSLE) and may impact other psychological and health-related outcomes. Mental health problems such as anxiety…Abstract Number: 087 • 2023 Pediatric Rheumatology Symposium
Delays in Care, Declines in Health, and Food Insecurity in Pediatric Systemic Lupus Erythematosus Patients During the COVID-19 Pandemic
Background/Purpose: The COVID-19 pandemic created dramatic societal disruptions. Social distancing and measures to reduce disease spread rapidly reshaped healthcare delivery. Recognizing the burden of frequent…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 35
- Next Page »